| Overview |
| bs-0714R |
| HPV16 E7 Polyclonal Antibody |
| IHC-P, IF(IHC-P) |
| Virus |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from HPV16 E7 protein |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. |
| Store at -20°C for 12 months. |
| Target |
| 1489079 |
| E7; Human Papilloma Virus; Human papillomavirus type 16 E7; Human papillomavirus type 16 E7; Protein E7; Human Papillomavirus 16 E7; HPV16 E7; E7 protein HPV16; VE7_HPV16. |
| Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro. |
| Application Dilution |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz